The association between adiponectin gene rs182052 polymorphism and cancer risk: a meta-analysis

BACKGROUND: The evidence for an association between the adiponectin gene (ADIPOQ) polymorphism rs182052 and cancer risk is inconsistent. We performed a meta-analysis to obtain more precise conclusions. METHODS: The PubMed, Embase, and Web of Science databases were searched until July 11, 2019. And seven epidemiology studies were retrieved, including 4,929 cases and 5,625 controls. Odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) were calculated to evaluate the strength of the association. RESULTS: The meta-analysis demonstrated that rs182052 significantly increased the risk of cancer under the allele, homozygote, dominant, and recessive models, based on an overall analysis (A vs. G: OR, 1.09, 95% CI, 1.03-1.15, P=0.003; AA vs. GG: OR, 1.20, 95% CI, 1.07-1.34, P=0.002; AA+GA vs. GG: OR, 1.12, 95% CI, 1.03-1.22, P=0.010; AA vs. GA+GG: OR, 1.12, 95% CI, 1.01-1.23, P=0.025). In the stratified analysis by ethnicity, rs182052 significantly increased the cancer risk in both Asian and Caucasian populations under one or several genetic models. In the stratified analysis by cancer type, rs182052 significantly increased the risk of renal cell carcinoma (RCC) under the five models. CONCLUSIONS: Meta-analysis based on present studies suggests that rs182052 can increase the cancer risk.